Tempus AI EVP Andrew Polovin sells shares price $45,459

Andrew Polovin, Govt Vice President and Common Counsel at Tempus AI, Inc. (NASDAQ:TEM), lately bought 1,130 shares of the corporate’s Class A typical inventory. The inventory has seen important volatility, dropping 7% prior to now week whereas sustaining a 28% achieve over the past six months. The transaction, dated December 16, 2024, amounted to $45,459, with shares bought at a weighted common value of $40.23. In response to the submitting, this sale was performed to cowl statutory tax withholding obligations associated to the vesting of restricted inventory models, as mandated by Tempus AI’s fairness incentive plans. Following this transaction, Polovin retains possession of 244,955 shares within the firm, which represents a stake in Tempus AI’s $6.1 billion market capitalization. The corporate maintains robust liquidity with a present ratio of two.69, indicating wholesome short-term monetary positioning. InvestingPro subscribers can entry 8 further key insights about Tempus AI’s monetary well being and market place.

In different current information, Tempus AI has been the main focus of a number of monetary companies following its current earnings report and acquisition of genetics agency, Ambry. Piper Sandler elevated Tempus AI’s value goal from $40 to $70, sustaining a impartial score. Stifel downgraded Tempus AI from Purchase to Maintain, however elevated its value goal to $65. Needham raised its value goal to $56 and maintained a Purchase score.

These changes got here on the heels of Tempus AI’s third-quarter outcomes, which exceeded market expectations, and the strategic acquisition of Ambry Genetics. The acquisition is predicted to introduce rapid genomics capabilities and important alternatives in knowledge and functions over time.

Tempus AI has additionally partnered with Avacta Therapeutics to make the most of AI in advancing oncology drug growth, offering Avacta entry to Tempus’s complete multimodal datasets. Moreover, Tempus AI’s Tempus ECG-AF system, which makes use of synthetic intelligence to determine sufferers at greater danger of atrial fibrillation/flutter, lately obtained FDA clearance. These are the current developments surrounding Tempus AI.

This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.